PLRX Logo

Pliant Therapeutics, Inc. (PLRX) 

NASDAQ
Market Cap
$782.58M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
667 of 774
Rank in Industry
361 of 432

Largest Insider Buys in Sector

PLRX Stock Price History Chart

PLRX Stock Performance

About Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic …

Insider Activity of Pliant Therapeutics, Inc.

Over the last 12 months, insiders at Pliant Therapeutics, Inc. have bought $0 and sold $1.97M worth of Pliant Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Pliant Therapeutics, Inc. have bought $0 and sold $7.6M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

List of Insider Buy and Sell Transactions, Pliant Therapeutics, Inc.

2024-07-10SalePresident and CEO
38,710
0.0701%
$11.56$447,4880.00%
2024-07-10SaleChief Financial Officer
10,911
0.0198%
$11.56$126,1310.00%
2024-07-10SaleChief Business Officer
9,900
0.0179%
$11.56$114,4440.00%
2024-07-10SaleChief Medical Officer
12,319
0.0223%
$11.56$142,4080.00%
2024-07-10SaleGeneral Counsel & Corp. Sec'y
7,656
0.0139%
$11.56$88,5030.00%
2024-01-17SalePresident and CEO
25,721
0.0414%
$17.23$443,173-22.44%
2024-01-17SaleChief Financial Officer
9,781
0.0157%
$17.23$168,527-22.44%
2024-01-17SaleChief Business Officer
9,786
0.0158%
$17.23$168,613-22.44%
2024-01-17SaleChief Medical Officer
10,295
0.0166%
$17.23$177,383-22.44%
2024-01-17SaleGeneral Counsel & Corp. Sec'y
5,197
0.0084%
$17.23$89,544-22.44%
2023-08-04SaleChief Business Officer
20,050
0.0337%
$20.01$401,201-24.96%
2023-08-03SaleChief Business Officer
14,869
0.0258%
$20.00$297,380-22.46%
2023-07-20SaleGeneral Counsel & Corp. Sec'y
4,755
0.0085%
$17.55$83,450-12.11%
2023-07-17SalePresident and CEO
70,150
0.1263%
$18.01$1.26M-13.00%
2023-07-17SaleChief Business Officer
17,937
0.0323%
$18.01$323,029-13.00%
2023-07-17SaleChief Financial Officer
19,771
0.0356%
$18.01$356,058-13.00%
2023-07-17SaleChief Medical Officer
22,321
0.0402%
$18.01$401,981-13.00%
2023-07-17SaleGeneral Counsel & Corp. Sec'y
12,778
0.023%
$18.01$230,120-13.00%
2023-04-03SaleGeneral Counsel & Corp. Sec'y
2,877
0.0052%
$26.79$77,066-35.48%
2023-03-30SalePresident and CEO
35,339
0.063%
$26.52$937,222-35.31%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Deep Track Capital Lp$85.67M9.535.75M0%+$00.39
BlackRock$69.37M7.724.66M-3.04%-$2.18M<0.01
T. Rowe Price$58.99M6.563.96M+4.57%+$2.58M0.01
Fidelity Investments$58.8M6.543.95M-0.43%-$252,122.92<0.01
First Light Asset Management$52.67M5.863.53M-1.58%-$846,066.704.44
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.